Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Kefford

Showing results (21-30 of 62) with videos related to

Pageof 7
Sort By:
ANZ Journal of Surgery|September 19, 2017
Neoadjuvant systemic therapy for breast cancer: the Westmead experienceAnnelise M Cocco, David Messer, Alexander Brown, et al.
Cancer|January 14, 2009
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanomaAhmad A Tarhini, Michael Millward, Paul Mainwaring, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2014
Acute Radiation Skin Toxicity Associated With BRAF InhibitorsTrish Pulvirenti, Angela Hong, Arthur Clements, et al.
Implementation Science : IS|May 29, 2020
Clinicians' attitudes and perceived barriers and facilitators to cancer treatment clinical practice guideline adherence: a systematic review of qualitative and quantitative literatureMia Bierbaum, Frances Rapport, Gaston Arnolda, et al.
Asia-Pacific Journal of Clinical Oncology|December 2, 2016
Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologistsVictoria Atkinson, Georgina V Long, Alexander M Menzies, et al.
American Journal of Therapeutics|January 14, 2014
Treatment algorithms in stage IV melanomaEnrique Espinosa, Jean-Jacques Grob, Reinhard Dummer, et al.
Investigational New Drugs|February 17, 2021
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignanciesSarina A Piha-Paul, Kyaw Z Thein, Paul De Souza, et al.
Case Reports in Oncological Medicine|August 9, 2014
Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma PatientsStephanie Du Four, Angela Hong, Matthew Chan, et al.
Investigational New Drugs|October 6, 2006
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanomaRichard Kefford, Jane McNeil Beith, Guy Arthur Van Hazel, et al.
Journal of Medical Genetics|October 7, 2018
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline <i>CDKN2A</i> mutationsHildur Helgadottir, Paola Ghiorzo, Remco van Doorn, et al.
Pageof 7

Showing results (21-30 of 62) with videos related to

Sort By:
Pageof 7
ANZ Journal of Surgery|September 19, 2017
Neoadjuvant systemic therapy for breast cancer: the Westmead experienceAnnelise M Cocco, David Messer, Alexander Brown, et al.
Cancer|January 14, 2009
A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanomaAhmad A Tarhini, Michael Millward, Paul Mainwaring, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 29, 2014
Acute Radiation Skin Toxicity Associated With BRAF InhibitorsTrish Pulvirenti, Angela Hong, Arthur Clements, et al.
Implementation Science : IS|May 29, 2020
Clinicians' attitudes and perceived barriers and facilitators to cancer treatment clinical practice guideline adherence: a systematic review of qualitative and quantitative literatureMia Bierbaum, Frances Rapport, Gaston Arnolda, et al.
Asia-Pacific Journal of Clinical Oncology|December 2, 2016
Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologistsVictoria Atkinson, Georgina V Long, Alexander M Menzies, et al.
American Journal of Therapeutics|January 14, 2014
Treatment algorithms in stage IV melanomaEnrique Espinosa, Jean-Jacques Grob, Reinhard Dummer, et al.
Investigational New Drugs|February 17, 2021
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignanciesSarina A Piha-Paul, Kyaw Z Thein, Paul De Souza, et al.
Case Reports in Oncological Medicine|August 9, 2014
Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma PatientsStephanie Du Four, Angela Hong, Matthew Chan, et al.
Investigational New Drugs|October 6, 2006
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanomaRichard Kefford, Jane McNeil Beith, Guy Arthur Van Hazel, et al.
Journal of Medical Genetics|October 7, 2018
Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline <i>CDKN2A</i> mutationsHildur Helgadottir, Paola Ghiorzo, Remco van Doorn, et al.
Pageof 7